Fig. 4

Clustered ranking plots based on SUCRA values of efficacies and efficacies with different CCRT regimens in the treatment of LA-NSCLC. A Clustered ranking plots based on SUCRA values of efficacies with different CCRT regimens in the treatment of LA-NSCLC. B Clustered ranking plots based on SUCRA values of toxicities with different CCRT regimens in the treatment of LA-NSCLC. Studies on the upper right corner have better efficacy or higher toxicity. A = CCRT (cisplatin + etoposide). B = CCRT (carboplatin + paclitaxel). C = CCRT (pemetrexed + carboplatin). CCRT = Concurrent Chemoradiotherapy. D = CCRT (pemetrexed + cisplatin). E = CCRT (docetaxel + cisplatin). F = CCRT (S-1 + cisplatin). G = CCRT (mitomycin + vindesine + cisplatin). H = CCRT (cisplatin + vinorelbine). I = CCRT (cisplatin). K = RT. L = CCRT (5-FU). LA-NSCLC = locally advanced non-small cell lung cancer. M = CCRT (paclitaxel + cisplatin). N = CCRT (irinotecan + carboplatin). O = CCRT (nedaplatin). ORR = overall response rate. OS = overall survival. P = CCRT (carboplatin + etoposide). Q = CCRT (paclitaxel). R = CCRT (carboplatin). SUCRA = surface under the cumulative ranking